Business Context and Reporting Period
This Form 6-K filing by DBV Technologies S.A. is dated March 22, 2017. The report serves as a notification of the filing of the company's 2016 "Document de Référence" with the French market authority (AMF) and its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission (SEC) for the fiscal year ended December 31, 2016.
Key Financial Metrics
The filing text does not provide specific financial values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural announcement directing investors to the full 2016 Annual Report (Form 20-F) and the "Document de Référence" for detailed financial data.
Material Changes
No material financial changes or comparative period data are disclosed in this specific filing. The document focuses on the availability of the annual reports rather than reporting specific operational or financial variances.
Guidance, Outlook, and Management Commentary
Management commentary is limited to the company's strategic focus on its proprietary Viaskin® technology platform, which utilizes epicutaneous immunotherapy (EPIT®). Key development programs mentioned include:
- Ongoing clinical trials for Viaskin Peanut and Viaskin Milk for food allergies.
- Preclinical development of Viaskin Egg.
- A human proof-of-concept clinical study of Viaskin Milk for Eosinophilic Esophagitis.
- Exploration of potential applications in vaccines and other immune diseases.
The filing does not contain specific forward-looking financial guidance, risk factors, or contingencies beyond the general context of clinical development.
Important Facts for Investor Verification
- Verify the detailed financial results for the year ended December 31, 2016, by accessing the Form 20-F on the SEC website or the "Document de Référence" on the AMF website.
- Confirm the current status of clinical trials for Viaskin Peanut and Viaskin Milk, as these are the primary drivers of the company's pipeline.
- Review the full Form 20-F for comprehensive risk factors related to clinical development and regulatory approvals, which are not detailed in this summary filing.
- Note that the company trades on Euronext Paris (Ticker: DBV) and the Nasdaq Global Select Market as American Depositary Shares (Ticker: DBVT).